Advertisement
Research Article| Volume 32, ISSUE 7, P580-594, October 01, 1992

Predictors of the course of tardive dyskinesia in patients receiving neuroleptics

  • Jenny Bergen
    Correspondence
    Address reprint request to Dr. Jenny Bergen, The Rozelle Hospital, P.O. Box 1, Rozelle New South Wales 2039, Australia.
    Affiliations
    From the Department of Community Medicine, Royal Prince Alfred Hospital, Australia

    Department of Public Health, University of Sydney, Australia
    Search for articles by this author
  • Rowena Kitchin
    Affiliations
    From the Department of Community Medicine, Royal Prince Alfred Hospital, Australia

    Department of Public Health, University of Sydney, Australia
    Search for articles by this author
  • Geoffrey Berry
    Affiliations
    From the Department of Community Medicine, Royal Prince Alfred Hospital, Australia

    Department of Public Health, University of Sydney, Australia
    Search for articles by this author
DOI:https://doi.org/10.1016/0006-3223(92)90071-7
Predictors of the course of tardive dyskinesia in patients receiving neuroleptics
Previous ArticleSignal-transducing G proteins and antidepressant Drugs: Evidence for modulation of α subunit gene expression in rat brain
Next ArticlePhysical aspects of the EEG in schizophrenics
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      As many patients still require maintenance neuroleptic medication, it is important to determine what factors affect the course of tardive dyskinesia (TD) during ongoing neuroleptic treatment. In this study the data are from a series of annual examinations using the Abnormal Involuntary Movement Scale (AIMS) in a cohort of outpatients. Average neuroleptic exposure at the commencement of the examinations was 10 yr. The data on AIMS scores at successive visits are analysed using autoregressive modeling. Two hundred thirty-five patients contributed the 678 pairs of examinations. Separate analyses are reported for orofacial, limb-truncal, and total AIMS scores. Different predictor variables emerged as important for orofacial and limb-truncal dyskinesia. Age, sex, being on anticholinergic medication, and two variables describing duration of neuroleptic exposure contributed to the outcome score for total AIMS score after 1 yr.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Barnes T.R.E.
        • Braude W.M.
        Akathisia variants and tardive dyskinesia.
        Arch Gen Psychiatry. 1985; 42: 874-878
        • Barnes T.R.E.
        • Kidger T.
        • Gore S.M.
        Tardive dyskinesia: a 3-year follow-up study.
        Psychol Med. 1983; 13: 71-81
        • Bergen J.A.
        • Carter N.B.
        • Craig J.
        • MacFarlane D.
        • Smith E.
        • Beumont P.J.V.
        AIMS ratings—repeatability.
        Br J Psychiatry. 1988; 152: 670-673
        • Bergen J.A.
        • Eyland E.A.
        • Campbell J.A.
        • Jenkings P.
        • Kellehear K.
        • Richards A.
        • Beumont P.J.V.
        The course of tardive dyskinesia in patients on long-term neuroleptics.
        Br J Psychiatry. 1989; 154: 523-528
        • Bergen J.A.
        • Griffiths D.A.
        • Rey J.M.
        • Beumont P.J.V.
        Tardive dyskinesia: fluctuating patient or fluctuating rater.
        Br J Psychiatry. 1984; 144: 498-502
        • Capstick N.
        Long-term fluphenazine decanoate maintenance dosage requirement of chronic schizophrenic patients.
        Acta Psychiatr Scand. 1980; 61: 256-262
        • Chouinard G.
        • Annable L.
        • Mercier P.
        • Ross-Chouinard A.
        A five-year follow-up study of tardive dyskinesia.
        Psychopharmacol Bull. 1986; 22: 259-263
        • Chouinard G.
        • Annable L.
        • Ross-Chouinard A.
        • Mercier P.
        A five-year prospective longitudinal study of tardive dyskinesia: Factors predicting appearance of new cases.
        J Clin Psychopharmacol. 1988; 8: 21S-26S
        • Chouinard G.
        • Annable L.
        • Ross-Chouinard A.
        • Nestoros J.N.
        Factors related to tardive dyskinesia.
        Am J Psychiatry. 1979; 136: 79-83
        • Cohen J.
        Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit.
        Psychol Bull. 1968; 70: 213-220
        • Fornazzari X.
        • Grossman H.
        • Thornton J.
        • Seeman M.V.
        Tardive dyskinesia: A five year follow-up.
        Can J Psychiatry. 1989; 34: 700-703
        • Gardos G.
        • Cole J.O.
        Problems in the assessment of tardive dyskinesia.
        in: Fann W.E. Smith R.C. David J.M. Domino E.F. Tardive Dyskinesia: Research and Treatment. SP Medical & Scientific Books, New York1980: 201-212
        • Gardos G.
        • Cole J.O.
        • Haskell D.
        • Marby D.
        • Paine S.
        • Moore P.
        The natural history of tardive dyskinesia.
        J Clin Psychopharmacol. 1988; 8: 31S-37S
        • Gardos G.
        • Perenyi A.
        • Cole J.O.
        • Samu I.
        • Kocsis E.
        • Casey D.E.
        Seven-year follow-up of tardive dyskinesia in Hungarian outpatients.
        Neuropsychopharmacology. 1988; 1: 169-172
        • Gerlach J.
        • Casey D.E.
        Tardive dyskinesia.
        Acta Psychiatr Scand. 1988; 77: 369-378
        • Glazer W.M.
        • Moore D.C.
        • Schooler N.R.
        • Brenner L.M.
        • Morgenstern H.
        Tardive dyskinesia A discontinuation study.
        Arch Gen Psychiatry. 1984; 41: 523-627
        • Glazer W.M.
        • Morgenstern H.
        Predictors of occurrence, severity, and course of tardive dyskinesia in an outpatient population.
        J Clin Psychopharm. 1988; 8: 10S-16S
        • Glazer W.M.
        • Morgenstern H.
        • Niedzwiecki D.
        • Hughes J.
        Heterogeneity of tardive dyskinesia: A multivariate analysis.
        Br J Psychiatry. 1988; 152: 253-259
        • Gureje O.
        Topographic subtypes of tardive dyskinesia in schizophrenic patients aged less than 60 years: relationship to demographic, clinical, treatment, and neuropsychological variables.
        J Neurol Neurosurg Psychiatr. 1988; 51: 1525-1530
        • Guy W.
        ECDEU Assessment Manual for Psychopharmacology. U.S. Department of Health, Education and Welfare, Washington DC1976: 534-537
        • Jeste D.V.
        • Potkin S.G.
        • Sinha S.
        • Feder S.
        • Wyatt R.J.
        Tardive dyskinesia—reversible and persistent.
        Arch Gen Psychiatry. 1979; 36: 585-590
        • Johnson D.A.W.
        • Pasterski G.
        • Ludlow J.M.
        • Street K.
        • Taylor R.D.W.
        The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences.
        Acta Psychiatr Scand. 1983; 67: 339-352
        • Kane J.M.
        • Woerner M.
        • Borenstein M.
        • Wegner J.
        • Lieberman J.
        Integrating incidence and prevalence of tardive dyskinesia.
        Psychopharmacol Bull. 1986; 22: 254-258
        • Kane J.M.
        • Woerner M.
        • Lieberman J.
        Tardive dyskinesia: Prevalence, incidence, and risk factors.
        J Clin Psychopharmacol. 1988; 8: 52S-56S
        • Kane J.M.
        • Woerner M.
        • Weinhold P.
        • Wegner J.
        • Kinon B.
        • Borenstein M.
        Incidence of tardive dyskinesia: Five-year data from a prospective study.
        Psychopharmacol Bull. 1984; 20: 387-388
        • Kolakowska T.
        • Williams A.O.
        • Ardern M.
        • Reveket M.A.
        Tardive dyskinesia in schizophrenics under 60 years of age.
        Biol Psychiatry. 1986; 21: 161-169
        • Mason A.S.
        • Granacher R.P.
        Clinical Handbook of Antipsychotic Drug Therapy. Brunner/Mazel, New York1980
        • Morton A.P.
        • Dobson A.J.
        Assessing agreement.
        Med J Austral. 1989; 150: 384-387
        • Nordic Dyskinesia Study Group
        Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden.
        Psychopharmacology. 1986; 90: 423-429
        • Richardson M.A.
        • Casey D.E.
        Tardive dyskinesia status: Stability or change.
        Psychopharmacol Bull. 1988; 24: 471-475
        • Robinson A.D.T.
        • McCreadie R.G.
        The Nithsdale Schizophrenia Survey. V. Follow-up or tardive dyskinesia at Math Eq years.
        Br J Psychiatry. 1986; 149: 621-623
        • Rosner B.
        • Munoz A.
        Autoregressive modelling for the analysis of longitudinal data with unequally spaced examinations.
        Stat Med. 1988; 7: 59-71
        • Schooler N.R.
        • Kane J.M.
        Research diagnoses for tardive dyskinesia.
        Arch Gen Psychiatry. 1982; 39: 486-487
        • Smith J.M.
        • Baldessarini R.J.
        Changes in prevalence, severity, and recovery in tardive dyskinesia with age.
        Arch Gen Psychiatry. 1980; 37: 1368-1373
        • Waddington J.L.
        • Youssef H.A.
        • Dolphin C.
        • Kinsella A.
        Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia.
        Arch Gen Psychiatry. 1987; 44: 907-915
        • Wistedt B.
        A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot fluphenthixol decanoate in chronic schizophrenic patients.
        Acta Psychiatr Scand. 1981; 64: 65-84
        • Wojcik J.D.
        • Gelenberg A.J.
        • LaBrie R.A.
        • Mieske M.
        Prevalence of tardive dyskinesia in an outpatient population.
        Comprehen Psychiatry. 1980; 21: 370-380
        • Yassa R.
        • Nair V.
        Mild tardive dyskinesia: an 8-year follow-up study.
        Acta Psychiatr Scand. 1989; 81: 139-140

      Article info

      Publication history

      Received in revised form: April 6, 1992
      Received: October 10, 1991

      Identification

      DOI: https://doi.org/10.1016/0006-3223(92)90071-7

      Copyright

      © 1992 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX